Washington, DC 20006-5349
HELPLINE
MESOTHELIOMA NEWS
Scroll to find news of interest to you, or search by category. The Mesothelioma Applied Research Foundation covers mesothelioma news for patients and their families. Our write-ups are heavily reliant on peer-reviewed medical research studies with input from mesothelioma experts from around the world but are also accessible to non-medical readers.
At the end of May, in a brand new virtual format, the annual meeting for the American Society of Clinical Oncology (ASCO) was one of
The Mesothelioma Applied Research Foundation strongly believes that every mesothelioma patient should have the opportunity to be seen by an appropriate mesothelioma expert, regardless of
Liz Darlison, head of services at Mesothelioma UK, spoke with Mary Hesdorffer, NP, about mesothelioma treatment in the United Kingdom during COVID-19 and in general. Liz is a
A new approach of anti-PD1 immunotherapy (atezolizumab) combined with bevacizumab (an agent that blocks the growth of new blood vessels therefore limiting the supply of
Join us next Tuesday, June 9 at 2:00 PM ET for a Meet the Mesothelioma Experts (MTME) interview with Dr. Zachary Horne on Facebook Live.
Anna Nowak, MD, PhD, speaks about immunotherapy and combination of immunotherapy and chemotherapy for mesothelioma patients. She also discusses COVID-19’s effects on mesothelioma in treatment in Australia.
A phase 2 immunotherapy clinical trial combining durvalumab, an immunotherapy drug, with standard treatment of Alimta (pemetrexed)/cisplatin has shown promising overall survival results. The study enrolled 55 patients and
Buerkley Rose, MSN, RN, discusses how the University of Chicago’s mesothelioma program has adapted during the COVID-19 pandemic: Clinical Trials: Paused. Telemedicine, including psycho-oncology services: Available. Surgery: